<>{"type": "commentary", "values": "tool:load_session_metadata:executing"}<><>{"type": "commentary", "values": "tool:rewrite_user_query:executing"}<><>{"type": "commentary", "values": "tool:generate_session_label:executing"}<><>{"type": "commentary", "values": "tool:load_session_metadata:executing"}<><>{"type": "commentary", "values": "tool:rewrite_user_query:executing"}<><>{"type": "commentary", "values": "tool:generate_session_label:executing"}<><>{"type": "thinking_step", "values": "Interpreting the user query as `Biocon Ltd`"}<><>{"type": "commentary", "values": "tool:guardrails_agent_as_tool:executing"}<><>{"type": "thinking_step", "values": "Interpreting the user query as `What is the current status and recent performance of Biocon Ltd in the healthcare sector?`"}<><>{"type": "commentary", "values": "tool:guardrails_agent_as_tool:executing"}<><>{"type": "commentary", "values": "tool:load_response_from_cache:executing"}<><>{"type": "commentary", "values": "tool:load_response_from_cache:executing"}<><>{"type": "commentary", "values": "tool:stock_and_sector_ner:executing"}<><>{"type": "commentary", "values": "tool:timeframe_extractor:executing"}<><>{"type": "commentary", "values": "tool:stock_and_sector_ner:executing"}<><>{"type": "commentary", "values": "tool:timeframe_extractor:executing"}<><>{"type": "thinking_step", "values": "Identified Entities: Stocks: BIOCON"}<><>{"type": "commentary", "values": "tool:orchestrator_agent_as_tool:executing"}<><>{"type": "commentary", "values": "tool:render_templates_from_cache:executing"}<><>{"type": "commentary", "values": "tool:generate_follow_ups:executing"}<><>{"type": "commentary", "values": "orchestrator:started"}<><>{"type": "commentary", "values": "orchestrator:planning"}<><>{"type": "commentary", "values": "agent:StockSectorAgent:started"}<><>{"type": "commentary", "values": "agent:StockSectorAgent:planning"}<><>{"type": "follow-up", "options": [{"label": "follow_up_1", "value": "How does Biocon Ltd's valuation compare to other pharma stocks?"}, {"label": "follow_up_2", "value": "What are the recent news events affecting Biocon Ltd?"}, {"label": "follow_up_3", "value": "Is Biocon Ltd a good buy at its current price?"}, {"label": "follow_up_4", "value": "What are Biocon Ltd's earnings growth prospects for the next year?"}]}<><>{"type": "thinking_step", "values": "Fetching comprehensive stock information for Biocon Ltd, including market price and fundamental metrics."}<><>{"type": "thinking_step", "values": "Fetching technical indicators such as SMA, EMA, RSI, and MACD for Biocon Ltd."}<><>{"type": "thinking_step", "values": "Fetching recent news headlines and summaries related to Biocon Ltd."}<><>{"type": "thinking_step", "values": "Fetching today's corporate actions for Biocon Ltd, including dividends and splits."}<><>{"type": "thinking_step", "values": "Identified Entities: Stocks: BIOCON; Sectors: healthcare"}<><>{"type": "commentary", "values": "tool:orchestrator_agent_as_tool:executing"}<><>{"type": "commentary", "values": "tool:render_templates_from_cache:executing"}<><>{"type": "commentary", "values": "tool:generate_follow_ups:executing"}<><>{"type": "commentary", "values": "orchestrator:started"}<><>{"type": "commentary", "values": "orchestrator:planning"}<><>{"type": "commentary", "values": "agent:StockSectorAgent:started"}<><>{"type": "commentary", "values": "agent:StockSectorAgent:planning"}<><>{"type": "follow-up", "options": [{"label": "follow_up_1", "value": "How is Biocon Ltd's earnings outlook for the next quarter?"}, {"label": "follow_up_2", "value": "Should I consider buying Biocon Ltd shares now?"}, {"label": "follow_up_3", "value": "What are the main factors affecting Biocon Ltd's stock price recently?"}, {"label": "follow_up_4", "value": "How does Biocon Ltd compare to other healthcare stocks in India?"}]}<><>{"type": "thinking_step", "values": "Fetching comprehensive stock information for Biocon Ltd, including price and valuation metrics."}<><>{"type": "thinking_step", "values": "Retrieving technical indicators for Biocon Ltd, such as moving averages and trend signals."}<><>{"type": "thinking_step", "values": "Collecting recent news headlines and sentiment summaries for Biocon Ltd."}<><>{"type": "commentary", "values": "final_answer:generating"}<><>{"type": "commentary", "values": "final_answer:generating"}<><>{"type": "commentary", "values": "orchestrator:completed"}<><>{"type": "commentary", "values": "tool:generic_output_guardrail:executing"}<><>{"type": "commentary", "values": "orchestrator:completed"}<><>{"type": "commentary", "values": "tool:generic_output_guardrail:executing"}<># Biocon Ltd (BIOCON) – Quick Research Note --- ## 📊 Snapshot (as of 2026-03-11 IST) | Metric | Value | |---|---:| | **Last Price** | ₹400.80 ⬆️ (+1.26%) | | **Market Cap** | ₹632.70 B (≈ $7.34 B) | | **P/E** | 83.33 ⬇️ (Sector 37.21) | | **P/B** | 2.27 ✅ (Sector 5.23) | | **ROE (2025)** | 7.03 % ⬆️ | | **ROCE (2025)** | 7.43 % ⬇️ (Sector 15.65) | | **Dividend Yield** | 0.15 % ➡️ | | **EPS (TTM)** | ₹4.81 | | **5‑Day Avg Volume** | 2.53 M shares | | **Technical Trend** | All SMA/EMA bullish; RSI 64.36 (neutral‑to‑bullish) | --- ## 🏥 Business Overview > **Biocon Ltd** – India’s largest biotech firm, focused on **generics, biosimilars, novel biologics** and **research services**. Core therapeutic areas: **Oncology, Diabetes, Immunology**. Operates >5 facilities across Bangalore, Hyderabad & Visakhapatnam. --- ## 📈 Financial Performance (FY 2022‑2025) | FY | Revenue (₹ bn) | Net Profit (₹ bn) | Profit Margin | EPS (₹) | |---|---:|---:|---:|---:| | 2022 | 88.74 | 6.48 | 9.40 % | 5.40 | | 2023 | 119.42 | 4.63 | 5.70 % | 3.85 | | 2024 | 157.23 | 10.23 | 8.69 % | 8.52 | | 2025 | 166.18 | 10.13 | 9.32 % | 8.44 | > **Trend:** Revenue grew **~87 %** over four years, profit margin recovered after a dip in 2023, driven by higher‑margin biosimilars and US‑FDA approvals. --- ## 💰 Valuation & Ratios | Ratio | 2025 | Sector | |---|---:|---:| | **P/E** | 83.33 ⬇️ | 37.21 | | **P/B** | 2.27 ✅ | 5.23 | | **ROE** | 7.03 % ⬆️ | — | | **ROCE** | 7.43 % ⬇️ | 15.65 % | | **PEG** | -92.59 ❌ | — | | **Dividend Yield** | 0.15 % ➡️ | — | > **Interpretation:** The stock trades at a **significant premium on earnings** but is **reasonably priced on book**. Negative PEG reflects inconsistent earnings growth; investors should focus on cash‑flow quality and pipeline milestones. --- ## 📊 Shareholding (as of 2025‑12‑01) | Holder | % Holding | |---|---:| | **Promoters** | 54.45 % | | **Foreign Institutional Investors (FII)** | 7.39 % | | **Domestic Institutional Investors (DII)** | 21.71 % | | **Public** | 16.45 % | | **Others** | — | > **Note:** Institutional participation is modest; any shift in FII/DII sentiment could move the stock. --- ## 💹 Cash‑Flow Highlights | FY | Operating CF (₹ bn) | Investing CF (₹ bn) | Financing CF (₹ bn) | Net CF (₹ bn) | |---|---:|---:|---:|---:| | 2022 | 11.77 | -16.99 | 2.42 | -2.80 | | 2023 | 18.52 | -142.82 | 130.49 | 6.19 | | 2024 | 29.54 | -10.04 | -23.33 | -3.83 | | 2025 | 40.61 | -2.34 | -18.54 | 19.73 | > **Takeaway:** 2025 shows a **strong operating cash inflow** and **positive net cash**, indicating improved liquidity. --- ## 📉 Technical Snapshot (2026‑03‑11) | Indicator | Value | Signal | |---|---:|---| | **SMA (10‑day)** | 389.69 | Bullish ⬆️ | | **EMA (10‑day)** | 389.06 | Bullish ⬆️ | | **RSI** | 64.36 | Neutral‑to‑Bullish 📈 | | **MACD** | 5.12 / 4.16 (hist 0.95) | Bullish 📈 | | **52‑Wk High / Low** | 424.95 / 300.25 | — | > **Implication:** Price sits **≈5 % below 52‑wk high** with all moving averages bullish, suggesting limited upside unless a catalyst (e.g., US‑FDA approval rollout) triggers a breakout. --- ## 🗞️ Recent News (Mar 2026) > **Biocon – Analyst Meet** → Participation in JP Morgan India Credit Investor Trip (11 Mar 2026). No UPSI disclosed. > **USFDA Approval – Liraglutide Injection** → Enables entry into the fast‑growing GLP‑1 obesity market; potential revenue uplift. --- ## 📊 Analyst Sentiment | Recommendation | % | |---|---:| | **Strong Buy** | 35.71 % | | **Buy** | 28.57 % | | **Hold** | 14.29 % | | **Sell** | 21.43 % | | **Strong Sell** | 0 % | > **Median Target Price:** ₹431.67 (≈ $5.01 M). Implies ~7.7 % upside from current price. --- ## ✅ Actionable Takeaways + **DO:** Monitor post‑approval sales traction for Liraglutide and any guidance updates; consider a **small‑to‑moderate position** if you seek exposure to biotech upside at a **reasonable book value**. + **DON’T:** Ignore the **high P/E**; the stock is expensive on earnings and may be vulnerable to earnings miss or broader market rotation away from high‑multiple pharma names. + **DON’T:** Overlook the **risk score (10/10)** – high volatility and valuation risk. *Data sourced from internal aggregation as of 2026‑03‑11. All figures are INR unless noted otherwise.* *This is for informational purposes, not investment advice.* # Biocon Ltd (BIOCON) – Short‑Term Snapshot (2026‑03‑11) --- ## 📊 Recent Price & Returns > **Current price** → **₹400.80** (↑ ₹5.00, **+1.26%**) > **Previous close** → ₹395.80 | Metric | Biocon | Industry | |---|---:|---:| | **Daily return** | **+1.10%** ⬆️ | +0.74% ⬆️ | | **Weekly return** | **+5.76%** ⬆️ | +2.72% ⬆️ | | **Monthly return** | **+7.01%** ⬆️ | **‑1.84%** ⬇️ | | **6‑mo return** | **+9.89%** ⬆️ | **‑7.13%** ⬇️ | | **YTD return** | **+27.11%** 📈 | +7.37% 📈 | --- ## 📈 Valuation & Fundamentals (FY 2025) > Median price target from 14 analysts: **₹431.67** (≈ $5.00 K) | Metric | Value | |---|---:| | **P/E** | 83.33 ⬇️ (Sector P/E 37.21) | | **P/B** | 2.27 ✅ (Sector P/B 5.23) | | **ROE** | 7.03% ⚖️ | | **ROA** | 2.50% ⚖️ | | **ROCE** | 7.43% ⚖️ (Industry 15.65%) | | **Revenue growth** | 5.69% 📈 (Industry 13.90%) | | **Profit growth** | ‑0.90% ⚖️ (Industry ‑166.16%) | | **Dividend yield** | 0.15% 📉 | | **PEG** | ‑92.59 (negative due to high PE) | --- ## 🛠 Technical Snapshot (as of 2026‑03‑11) | Indicator | Value | Interpretation | |---|---|---| | **SMA (10‑day)** | 391.07 (Bullish) | ⬆️ Support near current price | | **EMA (10‑day)** | 390.99 (Bullish) | ⬆️ Trend still up | | **RSI** | 63.14 | Neutral‑to‑overbought | | **MACD** | 4.35 / 3.35 / 0.996 | Positive momentum | | **Bollinger Bands** | Upper 400.12 • Mid 389.48 • Lower 378.84 | Price near upper band | | **ATR (14‑day)** | 9.22 | Average volatility ~₹9 | | **Vortex (+)** | 1.10 | ↑ Trend strength | | **Stoch %K / %D** | 74.32 / 65.83 | Approaching overbought | | **MFI** | 71.01 | Slightly overbought | > **Pivot levels** → Pivot 395.55, **Supports** S1 392.65 • S2 389.50 • S3 386.60, **Resistances** R1 398.70 • R2 401.60 • R3 404.75. --- ## 📰 News Highlights (Last 30 days) > **→** **Feb 25 2026** – *Biocon receives USFDA approval for Liraglutide Injection (GLP‑1 weight‑loss therapy).* This adds a high‑growth product to the pipeline and expands the company’s presence in the lucrative obesity market. > > **→** **Mar 5 2026** – *Management to attend JP Morgan India Credit Investor Trip.* No UPSI disclosed; indicates continued investor outreach. --- ## 👥 Analyst Sentiment | Rating | Count | % | |---|---:|---:| | **Strong Buy** | 5 | 35.71% | | **Buy** | 4 | 28.57% | | **Hold** | 2 | 14.29% | | **Sell** | 3 | 21.43% | | **Strong Sell** | 0 | 0.00% | Overall outlook: **Neutral** (Score 5/10). Risk score is high (**10/10**) reflecting valuation stretch and sector volatility. --- ## ✅ Actionable Take‑aways + **DO** consider a **partial entry** on pull‑backs toward the **S1 support (₹392.65)** with a target of the analyst median **₹431.67** (≈ +7.6%). + **DON’T** ignore the **high PE** and **risk score**; avoid large‑size positions until price consolidates below the 10‑day SMA. + **MONITOR** upcoming **USFDA filings** for the Liraglutide line and any **quarterly earnings** that could shift the PE multiple. --- *Disclaimer: This note is based solely on data available up to 2026‑03‑11 and is not investment advice. Investors should conduct their own due diligence and consider personal risk tolerance.*

Biocon Ltd Stock Analysis and Forecast